Back to Results
First PageMeta Content
Lysosomal Acid Lipase Deficiency / Wolman disease / Cholesteryl ester storage disease / Mucopolysaccharidosis / Hunter syndrome / Health / Rare diseases / Lipid storage disorders


SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS LEXINGTON, Mass., July 30, [removed]Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products
Add to Reading List

Document Date: 2014-08-04 12:07:09

Open Document

File Size: 335,66 KB

Share Result on Facebook

City

RESULTS LEXINGTON / /

Company

Hoffman-La Roche Inc. / Synageva BioPharma Corp. / /

Currency

USD / /

Event

FDA Phase / Earnings Announcement / Earnings Guidance / /

IndustryTerm

biopharmaceutical company developing therapeutic products / developed technology / manufacturing capabilities / /

MedicalCondition

mucopolysaccharidosis IIIB / broad LAL Deficiency / accelerated atherosclerosis / LAL Deficiency LAL Deficiency / rare diseases / disease / rare autosomal recessive lysosomal storage disease / lysosomal acid lipase deficiency / cirrhosis / Cholesteryl Ester Storage Disease / Wolman disease / rare disorders / diseases / Other Pipeline Programs The mucopolysaccharidoses / deficiency / advanced liver disease / LAL Deficiency / B syndrome / /

MedicalTreatment

enzyme replacement therapy / /

Organization

European Medicines Agency / Ministry of Health / U.S. Food & Drug Administration / /

Person

MPS IIIB / /

Position

animal model / /

Product

Fuzeon / SBC-103 / /

ProvinceOrState

Massachusetts / /

Technology

alpha / transplantation / /

URL

www.synageva.com / /

SocialTag